Page 5 - norgine-annual-report-2016

Norgine in 2016

Key highlights

Norgine brings transformative products to market which might not Everyone is valued and empowered
otherwise be available to patients in Europe, Australia and New Zealand to contribute to Vision 2020

Specialist products portfolio

Cancer and
MOVICOL ® Colonoscopy* XIFAXAN ® Supportive Other***
Care**
2016 €159 million €62.2 million €41.3 million €12.6 million €19.9 million

2015 €159 million €59.2 million €34 million €13.4 million €34.4 million
Workforce diversity
*MOVIPREP , KLEAN-PREP , ENDOCUFF VISION ® Over 1,000 employees
®
®
®
®
®
**DANTRIUM , SETOFILM , MUGARD , XEROTIN ® 14 sites in Europe, Australia and New Zealand 59% women 41% men
***ZIVEREL , AXID , DESTOLIT , GIPROCOL , NORGALAX , QUADRASA , NORTUSSINE ,
®
®
®
®
®
®
®
NORMACOL , CAMCOLIT ®
®
Norgine’s core values
Direct European commercial presence
% of total product sales
NL 2
Belux 3
Apls 4
Nordic 5
Australia & New Zealand 6 One Norgine Innovation Trustworthiness
Iberia 7
Italy 7
Other 7
France 15
UK 17
Germany 27

Dr Alastair Benbow Philippe Caroff
appointed as appointed as
Flexible partnerships Chief Development VP Manufacturing
& Medical Officer & Supply
Norgine and its subsidiary Arc Medical Ltd
VALEANT (NYSE: VRX and TSX: VRX) Norgine fully acquired
Norgine licensed PLENVU rights to SpePharm licensed ENDOCUFF VISION™ rights to Patient centricity is key to Norgine’s future
™
Valeant for the US and Canada Europe B.V. Olympus Corporation Of The Americas
for the US and Canada
Norgine divested its MENA operations and product rights to Acino Norgine continued to divest non-core products

Strengthen late stage pipeline
Over 12 million patients Norgine collaborated with
LYMPHOSEEK ® used Norgine’s key products MOVICOL , and provided support to
®
PLENVU ® European Medicines Agency (EMA) approved MOVIPREP and XIFAXAN ®1 26 patient organisations 2
®
Positive Phase III programme studies – a new LYMPHOSEEK 50 microgram kit for
®
NOCT, MORA, and DAYB
radiopharmaceutical preparation 1. XIFAXAN ® 550: COGNOS sales, (calculated assuming 130 day duration of therapy) / MOVICOL ® : 2016 actual sales, (calculated assuming 100 days of treatment on average per
year and per patient) / MOVIPREP ® : number of procedures assuming that one patient would have one procedure per year.
2. http://norgine.com/responsibility/transparency-public-declarations.
3 4